Pharmacological interactions of statins

Atherosclerosis Supplements

Volumn 3, Issue 1, 2002, Pages 35-40

  Paoletti, Rodolfo ^a   Corsini, Alberto ^a   Bellosta, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cytochrome P450; Drug interaction; Fibrate; HMG CoA reductase inhibitors; Rhabdomyolysis

Indexed keywords

ATORVASTATIN; AZITHROMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DILTIAZEM; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MEVINOLIN; MIBEFRADIL; NEFAZODONE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SIMVASTATIN; TROGLITAZONE; UNINDEXED DRUG; VERAPAMIL; WARFARIN; CYTOCHROME P450; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

BILIARY EXCRETION; BIOTRANSFORMATION; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG INTERACTION; DRUG SAFETY; HUMAN; HYPERTENSION; LIVER; LONG TERM CARE; MYOPATHY; MYOSITIS; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; DRUG TOLERANCE; HYPERCHOLESTEROLEMIA; MUSCLE DISEASE; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG TOLERANCE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MUSCULAR DISEASES; PYRROLES; RHABDOMYOLYSIS;

EID: 0036579876     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(02)00002-8     Document Type: Conference Paper

References (41)

1. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamics and pharmacokinetic properties of statins. Pharmacol. Ther. 84:1999;413-428.
2. Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Goodman, Gilman, editors. The pharmacological basis of therapeutics. 10th ed. New York: McGraw Hill, Medical Publishing Division, 2001. pp. 971-1002.
3. Corsini A., Maggi F.M., Catapano A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res. 31:1995;9-27.
4. Farmer J.A., Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 108:2000;351-352.
5. Gibaldi M. Pharmacokinetic variability-drug interactions. Biopharmaceutics and clinical pharmacokinetics. 4th ed. 1991;Lea & Febiger, Philadelphia.
6. Bays H.E., Dujovne C.A. Drug interactions of lipid-altering drugs. Drug Saf. 19:1998;355-371.
7. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19:1998;26-37.
8. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:1997;210-258.
9. Azie N.E., Brater D.C., Becker P.A., Jones D.R., Hall S.D. The interaction of diltiazem with lovastatin and pravastatin. Clin. Pharmacol. Ther. 64:1998;369-377.
10. Mousa O., Brater D.C., Sunblad K.J., Hall S.D. The interaction of diltiazem with simvastatin. Clin. Pharmacol. Ther. 67:2000;267-274.
11. Masica A.L., Azie N.E., Brater D.C., Hall S.D., Jones D.R. Intravenous diltiazem and CYP 3A-mediated metabolism. Br. J. Clin. Pharmacol. 50:2000;273-276.
12. Yeo K.R., Yeo W.W., Wallis E.J., Ramsay L.E. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. Br. J. Clin. Pharmacol. 48:1999;610-615.
13. Kanathur N., Mathai M.G., Byrd R.P. Jr., Fields C.L., Roy T.M. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn. Med. 94:2001;339-341.
14. Peces R., Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron. 89:2001;117-118.
15. Gruer P.J.K., Vega J.M., Mercuri M.F., Dobrinska M.R., Tobert J.A. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. J. Cardiol. 84:1999;811-815.
16. Anon F.D.A. Announce new drug-interaction warnings for mibefradil. Am. J. Health-Syst. Pharm. 55:1998;210.
17. Schmassmann-Suhijar D., Bullingham R., Gasser R., Schmutz J., Haefeli W.E. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet. 351:1998;1929-1930.
18. Wombolt D.G., Jackson A., Punn R., Smith S., McCune T.R., Williams P.B. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin. J. Clin. Pharmacol. 39:1999;310-312.
19. Igel M., Sudhop T., vonBergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur. J. Clin. Pharmacol. 57:2001;357-364.
20. Penzak S.R., Chuck S.K., Stajich G.V. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy. 20:2000;1066-1071.
21. Lin J.C., Ito M.K. A drug interaction between troglitazone and simvastatin. Diabetes Care. 22:1999;2104-2105.
22. Kyrklund C., Backman J.T., Kivisto K.T., Neuvonen M., Laitila J., Neuvonen P.J. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 68:2000;592-597.
23. Mogyorosi A., Bradley B., Showalter A., Schubert M.L. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J. Intern. Med. 246:1999;599-602.
24. Christians U., Jacobsen W., Floren L.C. Metabolism and drug interactions of 3hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Ther. 80:1998;1-34.
25. East C., Alivizatos P.A., Grundy S.M., Jones P.H., Farmer J.A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N. Engl. J. Med. 318:1988;47-48.
26. Weise W.J., Possidente C.J. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. Am. J. Med. 108:2000;351-352.
27. Tobert J.A. Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol. 62:1988;28J-34J.
28. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur. Heart J. 16:1995;5-13.
29. FDA safety alerts. Bayer voluntarily withdraws Baycol, August 8th 2001.
30. Backman J.T., Kyrklund C., Kivisto K.T., Wang J.S., Neuvonen P.J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 68:2000;122-129.
31. Kyrklund C., Backman J.T., Kivisto K.T., Neuvonen M., Laitila J., Neuvonen P.J. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69:2001;340-345.
32. Pauciullo P., Borgnino C., Paoletti R., Mariani M., Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia FACT study. Atherosclerosis. 150:2000;429-436.
33. Shek A., Ferrill M.J. Statin-fibrate combination therapy. Ann. Pharmacother. 35:2001;908-917.
34. Omar M.A., Wilson J.P., Cox T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann. Pharmacother. 35:2001;1096-1107.
35. Boyd R.A., Stern R.H., Stewart B.H., Wu X., Reyner E.L., Zegarac E.A., Randinitis E.J., Whitfield L. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J. Clin. Pharmacol. 40:2000;91-98.
36. Walker J.F. Simvastatin: the clinical profile. Am. J. Med. 87:(Suppl. 4A):1989;44S-46S.
37. Arnadottir M., Eriksson L.-O., Thysell H., Karkas J.D. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron. 65:1993;410-413.
38. Goldberg R., Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine A. Transplantation. 62:1996;1559-1564.
39. Olbricht C., Wanner C., Eisenhauer T., Kliem V., Doll R., Boddaert M., O'Grady P., Krekler M., Mangold B., Christians U. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine A-treated kidney graft patients after multiple doses. Clin. Pharmacol. Ther. 62:1997;311-321.
40. Regazzi M.B., Iacona I., Campana C., Raddato V., Lesi C., Perani G., Gavazzi A., Vigano M. Altered disposition of pravastatin following concomitant drug therapy with cyclosporine A in transplant recipients. Transplant Proc. 25:1993;2732-2734.
41. Ichimaru N., Takahara S., Kokado Y., Wang J.D., Hatori M., Kameoka H., Inoue T., Okuyama A. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis. 158:2001;417-423.